| Dr Tony Joseph Castillo Ii, MD | |
|
1 Nolte Dr, Kittanning, PA 16201-7111 | |
| (724) 543-8500 | |
| (724) 543-8497 |
| Full Name | Dr Tony Joseph Castillo Ii |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 15 Years |
| Location | 1 Nolte Dr, Kittanning, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437380862 | NPI | - | NPPES |
| 1030980940001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD456838 (Pennsylvania) | Secondary |
| 208M00000X | Hospitalist | MD456838 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Acmh Hospital | Kittanning, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Armstrong County Memorial Hospital | 9335051663 | 31 |
News Archive
A new study uncovers a gene expression signature that reliably identifies cancer cells whose survival is dependent on a common signaling pathway, even when the cells contain multiple other genetic abnormalities.
"During these tough budget times, citizens across the world rightfully question the effectiveness of government spending, including funds spent on foreign assistance," Daniel Yohannes, chief executive officer of the Millennium Challenge Corporation (MCC), writes in this Foreign Policy opinion piece.
Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies.
Ordinary people worry about the extra, and often burdensome, responsibilities which could come with scientists' promises of 'personalised medicine', according to evidence to be presented at a major two-day showcase of groundbreaking social science research into the whole field of genomics, funded by the Economic and Social Research Council (ESRC).
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.
› Verified 1 days ago
| Entity Name | Armstrong County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568577724 PECOS PAC ID: 9335051663 Enrollment ID: O20031104000468 |
News Archive
A new study uncovers a gene expression signature that reliably identifies cancer cells whose survival is dependent on a common signaling pathway, even when the cells contain multiple other genetic abnormalities.
"During these tough budget times, citizens across the world rightfully question the effectiveness of government spending, including funds spent on foreign assistance," Daniel Yohannes, chief executive officer of the Millennium Challenge Corporation (MCC), writes in this Foreign Policy opinion piece.
Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies.
Ordinary people worry about the extra, and often burdensome, responsibilities which could come with scientists' promises of 'personalised medicine', according to evidence to be presented at a major two-day showcase of groundbreaking social science research into the whole field of genomics, funded by the Economic and Social Research Council (ESRC).
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.
› Verified 1 days ago
| Entity Name | University Of Pittsburgh Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619935004 PECOS PAC ID: 8729990239 Enrollment ID: O20040308000883 |
News Archive
A new study uncovers a gene expression signature that reliably identifies cancer cells whose survival is dependent on a common signaling pathway, even when the cells contain multiple other genetic abnormalities.
"During these tough budget times, citizens across the world rightfully question the effectiveness of government spending, including funds spent on foreign assistance," Daniel Yohannes, chief executive officer of the Millennium Challenge Corporation (MCC), writes in this Foreign Policy opinion piece.
Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies.
Ordinary people worry about the extra, and often burdensome, responsibilities which could come with scientists' promises of 'personalised medicine', according to evidence to be presented at a major two-day showcase of groundbreaking social science research into the whole field of genomics, funded by the Economic and Social Research Council (ESRC).
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tony Joseph Castillo Ii, MD 1 Nolte Dr, Kittanning, PA 16201-7111 Ph: (724) 543-8500 | Dr Tony Joseph Castillo Ii, MD 1 Nolte Dr, Kittanning, PA 16201-7111 Ph: (724) 543-8500 |
News Archive
A new study uncovers a gene expression signature that reliably identifies cancer cells whose survival is dependent on a common signaling pathway, even when the cells contain multiple other genetic abnormalities.
"During these tough budget times, citizens across the world rightfully question the effectiveness of government spending, including funds spent on foreign assistance," Daniel Yohannes, chief executive officer of the Millennium Challenge Corporation (MCC), writes in this Foreign Policy opinion piece.
Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies.
Ordinary people worry about the extra, and often burdensome, responsibilities which could come with scientists' promises of 'personalised medicine', according to evidence to be presented at a major two-day showcase of groundbreaking social science research into the whole field of genomics, funded by the Economic and Social Research Council (ESRC).
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.
› Verified 1 days ago
Bernard John Glaser, PA Hospitalist Medicare: Medicare Enrolled Practice Location: 1 Nolte Dr, Kittanning, PA 16201 Phone: 724-543-8500 |